Hendrik Jan Ankersmit (Managing Board) is the scientific founder of Aposcience AG. He is a cardiac and thoracic surgeon working at the Medical University of Vienna at the Vienna General Hospital. He was laboratory head of the Christian Doppler Laboratory for Diagnosis & Regeneration of Cardiac and Thoracic Diseases (funding period: 2009 – 15). Currently, he is heading the FFG-project "APOSEC" (runtime: 2015-2018). His research interests are biomarkers for lung and heart diseases as well as the prevention of cardiac remodeling following myocardial infarction (MI) and wound healing with innovative cell based strategies.

Andreas Kronberger (Managing Board) covered national and international management positions in various pharmaceutical companies for more than 30 years. Most recently he served as General Manager for Baxter Healthcare Österreich GmbH and Actelion Pharmaceuticals Austria GmbH, a Janssen Company of Johson & Johnson. At Aposcience he is responsible for finances since 2016.
Helmut Hofbauer (Assistant to the Board of Directors), Dr phil. He administrated the Christian Doppler Laboratory for Cardiac and Thoracic Diagnosis & Regeneration from 2011-15; currently, he is in charge of the administration of the FFG-project "APOSEC" (runtime: 2015-2018).
Ghazaleh Gouya Board certified in Internal Medicine, Cardiology and Clinical Pharmacology, MD, and awarded Associate Professor in Internal Medicine, with more than 18 years of clinical and research experience in academia as well as for pharmaceutical companies. Ghazaleh takes leadership for the clinical development in the selected therapeutic areas for ApoScience.
Alfred Gugerell, Mag. Dr. rer. nat., is in charge of quality management and supports the administration of the FFG-project “APOSEC”. As a biologist, he did research on skin tissue regeneration, vascularization, and cutaneous wound healing. Since 2015 he works as a postdoc at the Department of Cardiology at the Medical University of Vienna in the field of stem cell transplantation after myocardial infarction.
Latest News

MarsyasI - clinical phase 1 study completed



Paper on content analysis of APOSEC recently published